Cryoport, Inc.CYRXEarnings & Financial Report
Cryoport, Inc. is a global provider of specialized temperature-controlled logistics and supply chain solutions focused on the life sciences, biopharmaceutical, and cell and gene therapy sectors. It partners with research institutions, biotech firms, and pharmaceutical manufacturers globally to support the safe transport of sensitive biological materials including clinical trial samples and advanced therapy products.
CYRX Q4 FY2025 Key Financial Metrics
Revenue
$45.5M
Gross Profit
$21.7M
Operating Profit
$-7.7M
Net Profit
$-8.0M
Gross Margin
47.8%
Operating Margin
-17.0%
Net Margin
-17.5%
YoY Growth
9.6%
EPS
$-0.19
Cryoport, Inc. Q4 FY2025 Financial Summary
Cryoport, Inc. reported revenue of $45.5M (up 9.6% YoY) for Q4 FY2025, with a net profit of $-8.0M (up 57.4% YoY) (-17.5% margin). Cost of goods sold was $23.7M, operating expenses totaled $29.5M.
Key Financial Metrics
| Total Revenue | $45.5M |
|---|---|
| Net Profit | $-8.0M |
| Gross Margin | 47.8% |
| Operating Margin | -17.0% |
| Report Period | Q4 FY2025 |
Cryoport, Inc. Annual Revenue by Year
Cryoport, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $176.2M).
Cryoport, Inc. Quarterly Revenue & Net Profit History
Cryoport, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $45.5M | +9.6% | $-8.0M | -17.5% |
| Q3 FY2025 | $44.2M | +15.4% | $-6.9M | -15.7% |
| Q2 FY2025 | $45.5M | +14.5% | $105.2M | 231.4% |
| Q1 FY2025 | $41.0M | +10.1% | $-12.0M | -29.2% |
| Q4 FY2024 | $41.5M | +665.3% | $-18.7M | -45.1% |
| Q3 FY2024 | $38.3M | -31.8% | $805.0K | 2.1% |
| Q2 FY2024 | $39.7M | -30.4% | $-78.0M | -196.4% |
| Q1 FY2024 | $37.3M | -40.6% | $-18.9M | -50.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.3M | $39.7M | $38.3M | $41.5M | $41.0M | $45.5M | $44.2M | $45.5M |
| YoY Growth | -40.6% | -30.4% | -31.8% | 665.3% | 10.1% | 14.5% | 15.4% | 9.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $942.8M | $852.3M | $701.8M | $703.5M | $699.8M | $773.9M | $774.3M | $765.0M |
| Liabilities | $470.7M | $452.2M | $283.2M | $301.6M | $301.0M | $258.5M | $261.1M | $262.4M |
| Equity | $472.2M | $400.1M | $418.6M | $401.9M | $398.8M | $519.1M | $513.3M | $502.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.3M | $-8.0M | $447000 | $-5.5M | $-4.3M | $-7.3M | $2.2M | $919000 |